Skip to content

Safety and effectiveness of low power laser treatment in glaucoma patients

Safety and efficacy of Subliminal cyclo-photocoagulation in treatment of glaucoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/10/037142
Enrollment
27
Registered
2021-10-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical Health Condition 2: H401- Open-angle glaucoma

Interventions

Intervention1: Subliminal Cyclophotocoagulation: The laser settings to be used are 2000mW of 810 nm infrared diode laser radiation set at the subliminal mode with a duty factor of 31.5% (Quantel Medic

Sponsors

JIPMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age >1yr, including both gender 2. Patients with advanced and refractory glaucoma, with an IOP > 21 mm Hg on maximal tolerated medical therapy with or without previous glaucoma surgical procedures, and 3. Patients who are poor candidates for additional filtering surgery or implantation of glaucoma drain- age devices.

Exclusion criteria

Exclusion criteria: 1. Patients who had undergone any intraocular surgery other than glaucoma surgery within 2 months before recruitment 2. Patients who had undergone previous conventional TSCPC 3. Patients with significant cataract 4. Patients with significant scleral thinning 5. Patients with ocular infection, inflammation in the study eye in the 2 years prior to enrolment

Design outcomes

Primary

MeasureTime frame
PERCENTAGE REDUCTION OF INTRAOCULAR PRESSURE AND SUCCESS RATE Timepoint: at 1 day, 1 week, and at 1, 3 and 6 months. A minimum follow up of 3 months will be required

Secondary

MeasureTime frame
MEAN POST OPERATIVE IOP, MEAN POST OPERATIVE BCVA, RETREATMENT OUTCOMES, COMPLICATIONS (UVEITIS, CATARACT, MYDRIASIS, HYPOTONY, MACULAR EDEMA, LOSS OF VISUAL ACUITY AT LAST FOLLOW UP)Timepoint: at 1 day, 1 week, and at 1, 3 and 6 months.

Countries

India

Contacts

Public ContactPriyanka R

JIPMER

subadoc@gmail.com7598500133

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026